Q&A with Brian Murphy MD, CEO/CMO, NEMUS Bioscience
Humans produce a range of chemical compounds called cannabinoids that keep the human body stable by binding to receptors on cell membranes and controlling the release of chemical messengers that regulate everything from how humans experience pain to our moods. While most people’s endocannabinoid systems naturally help maintain a state of homeostasis, or stability, conditions such as multiple sclerosis or treatments for diseases like cancer can throw off that balance. Introducing cannabinoids made outside the body might help. Marijuana also contains cannabinoids – at least 66 of them.
Drugs based on cannabinoids, which could treat ailments ranging from arthritis to epilepsy, hold untold potential for the pharmaceutical industry.
The BioConnection.com recently spoke with Dr. Brian Murphy, NEMUS Bioscience’s CEO and CMO on the potential of cannabinoid research.
Q: What is NEMUS Bioscience working on?
Murphy: NEMUS Bioscience (OTCQB: NMUS) was formed to bring a new class of medicinals, based on the 100+ cannabinoid molecules in the Cannabis sativa plant, to a variety of therapeutic markets, especially those of unmet medical need. Almost every organ in the body possesses cannabinoid receptors giving these compounds tremendous versatility in affecting the course of disease.
Q: What are the main diseases or symptoms you are attempting to target with cannabinoid research?
Murphy: The NEMUS developmental pipeline is currently focused on three therapeutic silos:
1) Palliative care addressing specific indications of chemotherapy-induced nausea and vomiting (CINV) and chemotherapy-induced peripheral neuropathy, a particularly severe pain syndrome associated with certain type of cancer chemotherapy.
2) Ophthalmology: the initial therapeutic indication being pursued is glaucoma, with initial animal studies in models of glaucoma exhibiting an average 45% reduction in IOP, exceeding current IOP reduction standards with currently approved medications and those in development using the same models.
3) Anti-infectives: Nemus is developing cannabinoid-based therapeutics against both bacterial and viral targets, with the initial therapeutic target in this silo being methicillin-resistant Staphylococcus aureus (MRSA). The current MRSA epidemic in the United States accounts for close to $4 billion in associated health-care costs as this bacterium has developed resistance to many antibiotics. Newer therapies are needed.
Q: Describe your partnership with the University of Mississippi and how has the partnership benefited your research?
Murphy: The University of Mississippi (UM) is the only entity in the United States currently licensed by the federal government to grow, cultivate, and research cannabinoids autonomously. The University has held that license since 1968 and has a tremendous amount of intellectual capital and experience in the chemistry and physiology of cannabinoid molecules. That library of molecules and associated intellectual property helps distinguishes us from other companies in the cannabinoid therapeutic space.
Q: What difficulties have you encountered working with pharmaceuticals derived from cannabis?
Murphy: While marijuana is not a legal substance, drug companies are permitted to work with and develop derivatives from the plant and develop these molecules into drugs. Many leading approved medicinals for cardiovascular disease, cancer, and anti-infectives are derived from plants or as is known in pharma development: botanically derived medications. There is a designated regulatory pathway from both the DEA and FDA for cannabinoids and NEMUS works diligently to be in compliance with those requirements. To-date, we have not experienced any unexpected challenges outside the norm in developing a new class of compounds to address diseases.
Q: What is your opinion on people who smoke/ eat marijuana to relieve painful physical/ mental symptoms? In other words, why are cannabinoids better than the plant itself?
Murphy: For patients who use plant-derived cannabinoids, there are a number of challenges that “pharmaceuticalized” cannabinoids can hope to overcome:
- a) with an approved drug, you know what you’re getting- with the plant, random analyses performed by regulatory labs have shown that the advertised content doesn’t always reflect what is in the plant
- b) with an approved drug, the cannabinoid is specifically designed to combat a particular disease process both in formulation, route of delivery, and mechanism of action. With plant-derived treatments, one-route of administration doesn’t always fit all diseases
- c) FDA approved medications are covered by insurance reimbursement; plant-derived cannabinoids have historically not been covered by insurance. A month’s supply of plant-derived cannabinoids can run into the hundreds of dollars versus a $5-$10 monthly copay for FDA approved medications
- d) pharmaceuticalized cannabinoids undergo a rigorous testing process (randomized, double-blind, placebo controlled clinical trials), Plant derived cannabinoids have not undergone this type of rigorous testing and in many cases, rely on anecdotal evidence where bias reporting can creep in; until this type of rigorous testing is conducted in plant-derived cannabinoids, marijuana dispensaries run the risk of violating FTC regulations if they make claims on the efficacy and safety of their products
Q: What has been your biggest success in your research so far?
Murphy: The biggest success has been validating our prodrug design in the molecular engineering of the cannabinoid molecule in animal studies that permit the therapy to enter the body with more predictable bioavailability and steady-state drug concentrations. These proprietary molecules are designed to optimize safety and efficacy by permitting routes of administration that bypass first-pass metabolism in the liver. We look forward to upcoming human testing to further validate the potential benefits of this drug design approach.
For more information, log on to www.nemusbiosciences.com